Results 191 to 200 of about 429,667 (356)

Evaluation of Drug Effectiveness and Controlled Release Profiles of Clay Minerals Loaded with Anti-Carcinogenic Agent as a Drug Delivery System on Leukemia

Cancer Management and Research
Mustafa Duran,1 Elif Kaga2 1Afyonkarahisar Health Sciences University Faculty of Medicine, Department of Internal Medicine, Hematology, Afyonkarahisar, Türkiye; 2Afyonkarahisar Health Sciences University Department of Medical Services and Techniques ...
Duran M, Kaga E
doaj  

Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy. [PDF]

Extracell Vesicles Circ Nucl Acids
Amreddy N, Srivastava A, Riedinger N, Ragothaman M, Zhao YD, Gali H, Munshi A, Ramesh R.   +7 more
europepmc   +1 more source

Nanostructured lipid carriers for topical drug delivery: A comprehensive review of design, mechanisms, and therapeutic advances

Mamta Kumari, Dipti Gohil, Piyushkumar Sadhu   +2 more
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Functionalization of carbon nanospheres with curcumin, polyethylene glycol and folic acid: potential use as drug carriers. [PDF]

RSC Adv
De Sales L, Bernal-Chávez SA, Campos-Delgado J.   +2 more
europepmc   +1 more source

Biomimetic Collagen Membranes as Drug Carriers of Geranylgeraniol to Counteract the Effect of Zoledronate. [PDF]

Biomimetics (Basel), 2023
Manzano-Moreno FJ, de Luna-Bertos E, Toledano-Osorio M, Urbano-Arroyo P, Ruiz C, Toledano M, Osorio R.   +6 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents' Delivery Against Lung Cancer: A Review. [PDF]

Drug Des Devel Ther
Liu Y, Yang B, Chen H, Liao Y, Zhang S, Yang J, Chen W, Liu H.   +7 more
europepmc   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Synthesis and Characterization of Water-Soluble EDTA-Crosslinked Poly-β-Cyclodextrins Serving as Ion-Complexing Drug Carriers. [PDF]

Materials (Basel)
Podgórniak Z, Musiał W, Kulus MJ, Łacny D, Budnik A, Urbaniak T.   +5 more
europepmc   +1 more source